Analyst predicts more Bavarian vaccine orders in Europe in light of monkeypox outbreak
As the EMA assesses the Danish firm’s smallpox vaccine within the monkeypox indication, a Sydbank analyst believes more orders are on the horizon.
by marketwire, translated by daniel pedersen
Following last week’s news that the European Medicines Agency (EMA) has initiated a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, there could be more orders on the way than the firm has accounted for in its current 2022 guidance, says Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
